Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Hypoglycemia - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 49 | Code: MRS - 18144


Global Markets Directs, Hypoglycemia Pipeline Review, H1 2015, provides an overview of the Hypoglycemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypoglycemia
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Hypoglycemia and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Hypoglycemia pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Hypoglycemia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Hypoglycemia Overview 6
Therapeutics Development 7
Pipeline Products for Hypoglycemia - Overview 7
Pipeline Products for Hypoglycemia - Comparative Analysis 8
Hypoglycemia - Therapeutics under Development by Companies 9
Hypoglycemia - Therapeutics under Investigation by Universities/Institutes 10
Hypoglycemia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hypoglycemia - Products under Development by Companies 13
Hypoglycemia - Products under Investigation by Universities/Institutes 14
Hypoglycemia - Companies Involved in Therapeutics Development 15
Biodel Inc. 15
USV Limited 16
XERIS Pharmaceuticals, Inc. 17
XOMA Corporation 18
Zealand Pharma A/S 19
Hypoglycemia - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
glucagon - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
glucagon - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
glucagon - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
glucagon biosimilar - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Peptide for Cardiovascular and Hypoglycemia - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
XOMA-358 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ZP-4207 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Hypoglycemia - Recent Pipeline Updates 37
Hypoglycemia - Dormant Projects 40
Hypoglycemia - Product Development Milestones 41
Featured News & Press Releases 41
Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program 41
Nov 17, 2014: Zealand advances its proprietary stable glucagon analogue for severe hypoglycemia in diabetes into clinical development 41
Nov 12, 2014: FDA and EMA Grant Orphan Designation to Xeris Pharmaceuticals' Soluble Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Patients 42
Jun 17, 2014: Zealand presented new data on ZP-GA-1 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions 43
Apr 24, 2014: Xeris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps 44
Oct 17, 2013: Xeris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation 45
Jul 03, 2013: Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference 45
Jun 22, 2013: Zealand Pharma Presents Preclinical Data On Hypoglycemic Drug ZP-GA-1 At 73rd ADA Scientific Sessions 45
Jun 06, 2013: Biodel Plans To Submit New Drug Application For Glucagon Rescue Product Candidate To Treat Severe Hypoglycemia 46
Dec 06, 2012: Biodel's Glucagon Obtains FDA Orphan Drug Designation To Prevent Hypoglycemia In Congenital Hyperinsulinism Population 47

Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Number of Products under Development for Hypoglycemia, H1 2015 7
Number of Products under Development for Hypoglycemia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Hypoglycemia - Pipeline by Biodel Inc., H1 2015 15
Hypoglycemia - Pipeline by USV Limited, H1 2015 16
Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H1 2015 17
Hypoglycemia - Pipeline by XOMA Corporation, H1 2015 18
Hypoglycemia - Pipeline by Zealand Pharma A/S, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Hypoglycemia Therapeutics - Recent Pipeline Updates, H1 2015 37
Hypoglycemia - Dormant Projects, H1 2015 40

List of Figures

Number of Products under Development for Hypoglycemia, H1 2015 7
Number of Products under Development for Hypoglycemia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing